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INTRODUCTION
Traditionally, pain had been defined as acute or
chronic pain, pain that lasted for a short time, or
pain that continued or recured for a longer period.
But these division were not one hundred percent
correct, because acute pain could become chronic
when untreated and chronic pain could have acute
exacerbations.1,2 Many ways could effectively treat
acute and chronic pain. Each of these options had
its own benefits and risks, no single option was
right for every patient.
Treatment options for acute and chronic pain:3
1) NSAIDs: nonselective and COX-2 selective; 2)
Opioids; 3) Local anesthesia; 4) Adjuvant therapy,
etc.
Opioid analgesics were usually considered a
standard drugs for analgesic efficacy, but physician
and patient concern about their side effects might
contribute to the problem of under management of
pain. Opioid analgesics were associated with ad-
verse effects that limited their utility in the hospital,
the most dangerous was respiratory depression.
Nausea, vomiting, and constipation occurred fre-
quently and were often intolerable.4,5 The addition
of nonopioid analgesic could improve pain control
and minimize adverse effects while decreasing the
needed dosage for opioids. COX-2 selective inhibi-
Tujuan: Membandingkan efektivitas Parecoxib 40 mg iv dengan
Morfin 5 mg iv dalam 24 jam pertama pascaoperasi laparotomi gine-
kologi.
Bahan dan cara kerja: Penelitian pendahuluan ini yang berupa
penelitian acak tersusun dilakukan pada 20 pasien di RSCM, dibagi
dalam kelompok eksperimen (40 mg iv Parecoxib) dan kelompok kelola
(Morfin 5 mg iv). Pemantauan dilakukan selama 24 jam. Efektivitas di-
ukur dengan t test dengan variabel VAS (Visual Analog Scale), MAP,
denyut jantung, efek samping, dan dosis penanggulangan yang diper-
lukan pada efek samping.
Hasil: Tidak terdapat perbedaan bermakna antara kedua kelompok
yang berhubungan dengan VAS, MAP, denyut jantung, nausea muntah,
dan pethidin tang diperlukan.
Kesimpulan: Tidak terdapat perbedaan bermakna antara kelompok
Parecoxib 40 mg iv dan Morfin 5 mg iv sebagai analgesik pascabedah
pada laparotomi ginekologi.
[Maj Obstet Ginekol Indones 2006; 30-4: 223-8]
Kata kunci: ginekologi, laparotomi, analgesia, terapi
Objective: To compare the efficacy of Parecoxib 40 mg iv (COX2 se-
lective inhibitor) with Morphine 5 mg iv in the first 24 hours in post
operative gynecologic laparotomy surgery.
Materials and methods: A preliminary study of clinical randomized
controlled trial had been conducted involving 20 subjects in Dr. Cipto
Mangunkusumo Hospital. Subjects were recruited according to inde-
pendent parallel design, which were categorized as experimental group
for parecoxib 40 mg iv treatment and control group fo morphine 5 mg
iv treatment. The subjects were monitored for 24 hours (0 min, 10 min,
6 hr, 12 hr, 18 hr and 24 hr) respectively and the effectiveness were ex-
amined using independent T-test with variables of VAS (Visual Analog
Scale), MAP, heart rate, side effects, and rescue dose needed (pethidine
bolus IV) to those groups, p < 0.05 was significant.
Results: There were no significant difference were found between
parecoxib 40 mg iv and morphine 5 mg iv treatment related to VAS,
MAP, heart rate, nausea, vomitus, and pethidine needs in the postopera-
tive gynecologic laparotomy surgery.
Conclusions: The difference between parecoxib 40 mg iv and mor-
phine 5 mg iv as post operative analgesics were not significant in post-
operative gynecologic laparotomy subjects.
[Indones J Obstet Gynecol 2006; 30-4: 223-8]
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tion e.g. parecoxib reduced pain and inflammation
without the adverse effects traditionally associated
with COX-1 inhibition or opioids.6,7
Because pain was often under treated there was
urgent need to educate both professionals and pa-
tients on effective safe management of pain and to
investigate new analgesic treatments to fill this
need.
Under treated pain could cause discomfort, fear,
anxiety, sleeplessness, and increased blood pressure
and heart rate, resulting longer recovery times and
unnecessary use of health care resources. Patients
needed to be educated about pain relief, what to
expect and how to report both their pain and the
degree of pain they were experiencing, and the
healthcare professional should use analgesics that
optimized pain relief while limiting side effects.
COX-2 selective inhibition reduced pain and in-
flammation without the adverse events traditional-
ly associated with COX-1 inhibition.
Hypothesis: parecoxib had better efficacy as post
operative analgesic in gynecologic surgery than
morphine.
Figure 1. This figure illustrated the pathways of pain, pain was transmitted as a nerve signal, and pain response was a complex
process that involves both peripheral nervous system (PNS) and central nervous system (CNS). The transduction of noxious
stimuli typically began with peripheral nociceptors. Signals from these nociceptors travelled to the dorsal horn of the spinal
cord and then along the spinothalamic tract to the thalamus and cortex of the brain. COX-2 contributed to increase pain sensitivity
peripherally at the nociceptor as well as centrally at the dorsal horn.8
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METHODS
Twenty patients scheduled for elective surgery were
studied prospectively. After acquisition of ethical
clearance and informed consent these patients were
admitted to the study, age between 20 and 50 with
normal body weight (± 20%), good general condi-
tion, underwent elective gynecologycal surgery with
general anesthesia in Dr. Cipto Mangunkusumo Hos-
pital, Jakarta.
They were divided into two groups in random:
experimental group (Parecoxib group) and control
group (Morphine group). All patients were pre-
medicated with 2.5 mg midazolam and 50 mg
pethidine. 10 patients received 40 mg Parecoxib IV
post operatively; the other 10 patients received 5
mg morphine post operatively. All of the patients
were monitored for 24 hours (0 min, 10 min, 6 hr,
12 hr, 18 hr and 24 hr respectively) started in the
PACU and in the ward, asessment of the variables
including: VAS (Visual Analog Scale), MAP, heart
rate, side effects, and rescue dose needed (pethi-
dine bolus IV).
Parecoxib and morphine were given to patients
when they started complaining pain.
Pain Score (VAS)
Asessment start from the first 10 minute, 6 hr, 12
hr, 18 hr and 24 hr post operative respectively.
MAP and Heart Rate
MAP were computed using variable diastolic and
systolic blood pressure. Studied in 24 hour in the
same period as above as VAS and heart rate.
Figure 2. COX-2 played an important role in both peripheral and central mechanisms of pain, contributing to the development
of inflammatory pain sensitivity. Induction of COX-2 in the CNS resulted in an increased production of central prostaglandins,
which were involved in central sensitization.9
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Side Effects
The side effects in the both group were noted: nau-
sea, vomitus, and pruritus.
Pethidine Rescue Dose
Were given intravenously when the VAS value
above 50.
Statistical Analysis
Statistical analysis for this clinical trial of pare-
coxib 40 mg iv and morphine 5 mg iv were using
unpaired T-test, p value < 0.05 were considered sig-
nificant.
RESULTS
Anthropometrical Characteristics
Twenty patients were included in preliminary study,
the age average were 39.5 years in parecoxib and
41.2 years in morphine group. There were no dif-
ferences in body weights between parecoxib (54.3
kg) and morphine (54 kg).
Table 1. Anthropometrical Characteristics between Parecoxib 40
mg iv and Morphine 5 mg iv Group (n = 20)
Variable Mean (SD)
Parecoxib 40 mg iv Morphine 5 mg iv
Age (years)
Body Weight (kg)
Height (cm)
Systolic Blood
Pressure (mmHg)
Diastolic Blood
Pressure (mmHg)
Heart Rate (times/
minute)
 39.5
 54.3
 156.7
126
 81
  81.3
(8.18)
(9.35)
 (6.11)
(11.74)
(7.38)
(9.48)
 41.2
54
158.4
114.8
 72.5
 84.2
(7.24)
(6.04)
(3.20)
(9.85)
(7.91)
(9.82)
Comparison between Parecoxib 40 mg iv and
Morphine 5 mg iv in VAS, MAP, and Heart Rate
Table 2 showed the comparison of VAS, MAP, and
heart rate that were monitored for 24 hours between
patients who were treated with parecoxib 40 mg iv
and morphine 5 mg iv. There were no significant
differences between the groups, p value > 0.05.
Table 2. The Differences between Parecoxib 40 mg iv and Morphine 5 mg iv Group in VAS, MAP, and Heart Rate
Variable
Mean (SD) 95% CI
p
Parecoxib 40 mg iv Morphine 5 mg iv Lower Upper
VAS
 0 minute
10 minute
 6 hr
12 hr
18 hr
24 hr
71
51
 39.50
37
 33.50
 34.50
(23.78)
(20.66)
(22.29)
(14.76)
(12.92)
(11.17)
72
55
 36.50
 35.50
 33.50
 29.50
(14.76)
( 7.82)
(12.70)
(14.42)
(11.07)
(10.66)
-19.59
-18.67
-14.05
-12.21
-11.30
 -5.26
17.59
10.67
20.05
15.21
11.30
15.26
0.276
0.077
0.191
0.812
0.601
0.682
MAP
 0 minute
10 minute
 6 hr
12 hr
18 hr
24 hr
 92.20
 91.60
91
 90.33
85
 87.67
(12.19)
(13.28)
(16.71)
( 9.09)
( 9.33)
( 6.86)
 85.07
 88.7
 83.83
83
85
86
(14.27)
(14.31)
(11.11)
(10.82)
( 9.33)
( 8.43)
 -5.33
-10.07
 -6.16
 -2.06
 -8.77
 -5.56
19.60
15.87
20.50
16.72
 8.77
 8.89
0.503
0.949
0.589
0.797
0.913
1.000
Heart Rate
 0 minute
10 minute
 6 hr
12 hr
18 hr
24 hr
89.1
87.4
84.5
88.4
88.4
85.4
(18.28)
(17.94)
(10.87)
(13.06)
( 8.88)
( 6.87)
89
 84.8
89
 88.4
 87.6
 87.4
(18.09)
(20.24)
(15.81)
(14.96)
( 9.28)
( 9.14)
-16.99
-15.37
-17.25
-13.19
 -7.73
 -9.60
17.19
20.57
 8.25
13.19
 9.33
 5.60
0.910
0.598
0.600
0.900
0.956
0.774
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Nausea, Vomitus, and Pruritus between Pareco-
xib 40 mg iv and Morphine 5 mg iv
Both parecoxib and morphine groups had not sig-
nificant difference in side effects of nausea, vomi-
tus, and pruritus.
Table 3. The Differences Between Parecoxib 40 mg iv and Mor-
phine 5 mg iv Group in Nausea, Vomitus, and Pruritus
Group
Parecoxib 40 mg iv Morphine 5 mg iv
Total p
n (%) n (%)
Nausea
Yes
No
7 (70)
3 (30)
7 (70)
3 (30)
14
6
> 0.05
Vomitus
Yes
No
3 (30)
7 (70)
2 (20)
8 (80)
5
15
> 0.05
Pruritus
Yes
No
 0 (  0)
10 (100)
 0 (  0)
10 (100)
0
20
> 0.05
Rescue Drug Dose
Studied the consumption of the pethidine. In 10
minutes, patients in the morphine group got more
pethidine than parecoxib group but there were not
significant difference. After 10 minutes until 24
hours there were not significant differences either.
DISCUSSION
In our hypothesis, we thought that parecoxib iv
would have superior efficacy over morphine iv, as
we could see from the studies by Barton et al and
Rasmussen et al10,11 that had demonstrated single
dose parecoxib 40 mg iv had a rapid onset and mag-
nitude of analgesia, and superior analgesic efficacy
to a single dose morphine 4 mg intravenously, in
our study we used parecoxib 40 mg iv comparable
to 5 mg morphine (1 mg higher dose), that’s why
we found that the difference in analgesia and effi-
cacy not significant in the statistic analysis.
In studies to date, parecoxib sodium had pro-
perties that were typical of COX-2 selective agents;
it was nonulcerogenic and did not affect platelet
function/bleeding.12-14 In addition, parecoxib sodi-
um was useful in combination with opioids as a
part of a multimodal regimen to relieve pain. These
opioid-sparing effects had been observed in patients
who underwent total knee arthroplasty15 and la-
paroscopic cholectystectomy.16 In our study, the
used of pethidine as rescue dose showed these phe-
nomena in combination with parecoxib or mor-
phine.
In conclusion, this study indicated that the COX-
2-selective analgesic anti-inflammatory agent pare-
coxib was an effective analgesic in combination
with opioids (pethidine) but we still needed bigger
population to know more findings suggested pare-
coxib would be an effective and well-tolerated in-
Graphic 1. The Frequencies of Pethidine Needed in Parecoxib and Morphine Treatment Group
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jectable analgesic for management of postoperative
pain after gynecologic surgery.
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